4. Smith & Nephew – Sports Medicine, Trauma and Reconstruction
2018 revenue: $3.629 billion
Smith & Nephew’s knee implants business grew 3%, to more than $1 billion in 2018, and its hip implants business was up 2% to $613 million.
Officials at Smith & Nephew (NYSE:SNN) are excited about the company’s dual-mobility technology for hip implants, which they say protects against dislocation without compromising the device’s range of motion, CEO Namal Nawana said during a February earnings call transcribed by Seeking Alpha.
London-based Smith & Nephew used the AAOS meeting in Las Vegas in March to introduce Navio 7.0, the latest software for its hand-held robotic surgical system. Expected to launch during the second half of 2019, the Navio 7.0 will include a new intuitive interface, expanded surgical preferences and streamlined workflow that may reduce surgery time. It’ll include hip software acquired through Smith & Nephew’s purchase of Brainlab’s orthopedic joint reconstruction business.
“We are a very relevant part of the overall robotic placements and units in the world today,” Nawana said of Navio.
Smith & Nephew in recent years has bolted on new technologies through acquisitions, including Rotation Medical and its regenerative shoulder repair treatment, and Ceterix Orthopaedics and its NovoStitch Pro knee repair device.
You may also like: